✦ LIBER ✦

Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness

✍ Scribed by da Costa Miranda, Vanessa; de Souza Fêde, Ângelo Bezerra; dos Anjos, Carlos Henrique; da Silva, Juliana Ribeiro; Sanchez, Fernando Barbosa; da Silva Bessa, Lyvia Rodrigues; de Paula Carvalho, Jesus; Filho, Elias Abdo; de Freitas, Daniela; Del Pilar Estevez Diz, Maria

Book ID: 121449139
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 392 KB
Volume: 132
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2013.12.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sorafenib in combination with carboplati

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

✍ Martin Pölcher; Meike Eckhardt; Christoph Coch; Matthias Wolfgarten; Kirsten Küb 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 203 KB

Preliminary results of neoadjuvant chemo

Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery

✍ Sun-Joo Lee; Byoung-Gie Kim; Jeong-Won Lee; Chang-Soo Park; Je-Ho Lee; Duk-Soo B 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

Comparison of Platinum-based Neoadjuvant

Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer

✍ Sayyah-Melli, Manizheh; Zonoozi, Gita Kashi; Hashemzadeh, Shahryar; Esfahani, Al 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 375 KB

Improved tolerance of primary chemothera

Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients

✍ Amanda Nickles Fader; Vivian von Gruenigen; Heidi Gibbons; Fadi Abushahin; David 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 344 KB

First-line chemotherapy with epidoxorubi

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

✍ A Romanini; L Tanganelli; F Carnino; A Fanucchi; R Lionetto; S Pastorino; S Cosi 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Feasibility of interval cytoreduction fo

Feasibility of interval cytoreduction following neoadjuvant chemotherapy with carboplatin, weekly paclitaxel, and bevacizumab for advanced ovarian cancer – A phase I study

✍ Salani, R.; O’Malley, D.; Copeland, L.; Cohn, D.; Fowler, J.; Eisenhauer, E. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 216 KB